Mersana Therapeutics (NASDAQ:MRSN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Briefing.com reports. The firm had revenue of $9.25 million during the quarter, compared to analysts’ expectations of $8.50 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative return on equity of 282.36%. Mersana Therapeutics’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.52) earnings per share.

Mersana Therapeutics Stock Performance

Shares of Mersana Therapeutics stock traded up $0.25 during trading on Friday, hitting $2.71. 2,807,129 shares of the stock were exchanged, compared to its average volume of 1,668,868. The stock has a market capitalization of $328.72 million, a price-to-earnings ratio of -1.81 and a beta of 1.61. The company has a current ratio of 3.36, a quick ratio of 3.36 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average price of $4.16 and a 200-day moving average price of $3.09. Mersana Therapeutics has a 1-year low of $0.80 and a 1-year high of $9.62.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRSN. Guggenheim upgraded Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Thursday, February 29th. Robert W. Baird increased their target price on shares of Mersana Therapeutics from $1.00 to $5.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. raised Mersana Therapeutics from an “underweight” rating to a “neutral” rating and set a $5.00 price target for the company in a report on Tuesday, March 19th. Wedbush raised Mersana Therapeutics from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $2.00 to $7.00 in a report on Thursday, February 29th. Finally, BTIG Research raised Mersana Therapeutics from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.29.

View Our Latest Report on MRSN

About Mersana Therapeutics

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Featured Stories

Earnings History for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.